Ascentage Pharma Secures China IND Clearance for BTK Degrader APG-3288

summarizeSummary

Ascentage Pharma announced that its novel BTK degrader, APG-3288, received IND clearance from China's CDE, enabling a Phase I clinical study for hematologic malignancies.

check_boxKey Events

• China CDE IND Clearance for APG-3288

  Ascentage Pharma's novel BTK degrader, APG-3288, received Investigational New Drug (IND) clearance from the China Center for Drug Evaluation (CDE).

• Advances Global Clinical Development

  This clearance, following a recent U.S. FDA IND clearance on January 7, 2026, enables a multicenter Phase I clinical study in China for patients with relapsed/refractory hematologic malignancies.

• Strengthens Hematologic Malignancy Pipeline

  The approval further strengthens Ascentage Pharma's pipeline in hematologic malignancies, building on its existing approved products in China.

auto_awesomeAnalysis

This IND clearance from the China CDE for APG-3288 is a significant positive development, expanding the drug's global clinical development program. Following the recent U.S. FDA IND clearance on January 7, 2026, it underscores the company's robust capabilities in targeted protein degradation and its commitment to addressing unmet medical needs in cancer across major markets. This milestone allows the company to initiate a Phase I study in China, further progressing its pipeline in hematologic malignancies.